Michael Silverberg to Neoplasms
This is a "connection" page, showing publications Michael Silverberg has written about Neoplasms.
Connection Strength
4.862
-
Excess Mortality in Persons with Concurrent HIV and Cancer Diagnoses: A Retrospective Cohort Study. Cancer Epidemiol Biomarkers Prev. 2024 Dec 02; 33(12):1698-1705.
Score: 0.682
-
Timing of Antiretroviral Therapy Initiation and Risk of Cancer Among Persons Living With Human Immunodeficiency Virus. Clin Infect Dis. 2021 06 01; 72(11):1900-1909.
Score: 0.535
-
Cumulative Incidence of Cancer Among Persons With HIV in North America: A Cohort Study. Ann Intern Med. 2015 Oct 06; 163(7):507-18.
Score: 0.361
-
Survival among HIV-infected and HIV-uninfected individuals with common non-AIDS-defining cancers. Cancer Epidemiol Biomarkers Prev. 2015 Aug; 24(8):1167-73.
Score: 0.346
-
Factors contributing to risk for cancer among HIV-infected individuals, and evidence that earlier combination antiretroviral therapy will alter this risk. Curr Opin HIV AIDS. 2014 Jan; 9(1):34-40.
Score: 0.320
-
Exposure to antiretroviral therapy and risk of cancer in HIV-infected persons. AIDS. 2012 Nov 13; 26(17):2223-31.
Score: 0.296
-
HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev. 2011 Dec; 20(12):2551-9.
Score: 0.276
-
New insights into the role of HIV infection on cancer risk. Lancet Oncol. 2009 Dec; 10(12):1133-4.
Score: 0.241
-
HIV infection and the risk of cancers with and without a known infectious cause. AIDS. 2009 Nov 13; 23(17):2337-45.
Score: 0.240
-
Do antiretrovirals reduce the risk of non-AIDS-defining malignancies? Curr Opin HIV AIDS. 2009 Jan; 4(1):42-51.
Score: 0.226
-
Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS. 2007 Sep 12; 21(14):1957-63.
Score: 0.207
-
AIDS-defining and non-AIDS-defining malignancies: cancer occurrence in the antiretroviral therapy era. Curr Opin Oncol. 2007 Sep; 19(5):446-51.
Score: 0.206
-
Brief Report: Protease Inhibitors Versus Nonnucleoside Reverse Transcriptase Inhibitors and the Risk of Cancer Among People With HIV. J Acquir Immune Defic Syndr. 2024 Aug; 96(4):393-398.
Score: 0.167
-
The forecasted prevalence of comorbidities and multimorbidity in people with HIV in the United States through the year 2030: A modeling study. PLoS Med. 2024 Jan; 21(1):e1004325.
Score: 0.160
-
Cancer-Attributable Mortality Among People With Treated Human Immunodeficiency Virus Infection in North America. Clin Infect Dis. 2017 Aug 15; 65(4):636-643.
Score: 0.103
-
HIV Infection, Immunosuppression, and Age at Diagnosis of Non-AIDS-Defining Cancers. Clin Infect Dis. 2017 02 15; 64(4):468-475.
Score: 0.099
-
Prevalence of non-HIV cancer risk factors in persons living with HIV/AIDS: a meta-analysis. AIDS. 2016 Jan; 30(2):273-91.
Score: 0.092
-
Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers. AIDS. 2013 Jun 01; 27(9):1433-41.
Score: 0.077
-
The epidemiology of herpes zoster in patients with newly diagnosed cancer. Cancer Epidemiol Biomarkers Prev. 2013 Jan; 22(1):82-90.
Score: 0.074
-
HIV infection, aging, and immune function: implications for cancer risk and prevention. Curr Opin Oncol. 2012 Sep; 24(5):506-16.
Score: 0.073
-
Cancer screening in patients infected with HIV. Curr HIV/AIDS Rep. 2011 Sep; 8(3):142-52.
Score: 0.068
-
CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS. 2008 Apr 23; 22(7):841-8.
Score: 0.013